AUTH/2703/3/14: Anonymous consultant haematologist v Chugai (Granocyte) — no breach | PMCPA Case

📊

Key facts

⌄

Case number	AUTH/2703/3/14
Complainant	Anonymous, non-contactable consultant haematologist (district general hospital)
Company	Chugai
Product	Granocyte (lenograstim)
Main issues alleged	Inaccurate/misleading information; implied extrapolation from healthy donor data to neutropenic patients; EBMT recommendation presented as stipulation; inaccurate NHS commissioning/reimbursement statements; wasting time/ethical conduct
Applicable Code year	2014
Clauses considered	Clause 2, Clause 9.1, Clause 15.2, Clause 7.2, Clause 7.4, Clause 15.9
Panel decision	No breach of the Code
Complaint received	06 March 2014
Case completed	11 April 2014
Appeal	No appeal
Sanctions	None

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

An anonymous, non-contactable consultant haematologist complained about a meeting with a Chugai representative promoting Granocyte (lenograstim).
Allegations included: the rep showed information about G-CSF use in healthy donors that was not relevant to a non-transplant district general hospital and wasted time.
The complainant alleged the rep implied that results in healthy donors could be extrapolated to neutropenic patients (who are typically unwell with cancer and post-chemotherapy/radiotherapy).
The complainant challenged a slide quoting the European Group for Blood and Marrow Transplants (EBMT), alleging it was presented as a stipulation rather than a recommendation.
The complainant also alleged the rep told a senior nurse that Granocyte commissioning/reimbursement came directly from the new NHS commissioning board (NHS England) rather than local CCGs, implying full reimbursement.
Chugai interviewed all ten Granocyte-promoting representatives, provided the Granocyte e-sales aid and briefing document, and stated no KPI/metric compelled “tick box” visits; e-sales aid tracking was said to be regional page-use analytics.
Chugai provided NHS England directly-purchased products list evidence (link and screenshot) indicating Granocyte was directly commissioned/reimbursed by NHS England.

⚖️

⌄

No breach of the Code was ruled for all allegations.
The Panel found the complainant did not provide supporting material and, being non-contactable, could not be asked for further detail; the burden of proof was not met on the balance of probabilities.
The Panel considered the materials provided (e-sales aid and briefing document) did not support the alleged extrapolation claim or misleading implication about EBMT wording.
The Panel did not consider it unreasonable for secondary care haematologists to be informed about tertiary-unit use (mobilisation) given follow-on care may occur in district general hospitals.
The Panel did not consider it established that the representative gave inaccurate reimbursement information to the senior nurse, and found no evidence Chugai incorrectly briefed representatives on reimbursement.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access